Why I’d still buy this growth stock even after today’s 20% spike

These two smaller companies are flying high today as investors seek to take advantage of recent strong results, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug discovery and development specialist Immupharma (LSE: IMM) is flying today, its share price up a thumping 24%. That’s almost doubled in less than a fortnight, rising from around 51p on 26 September to 96p today. I reckon it could have further to go.

Bought the pharm

I was looking at Immupharma over the weekend and clearly I was not the only one. Others were also digesting the company’s recent positive news and subsequent share price spike and decided there was more to come. The London-headquartered company, which has Swiss and French operations, aims to develop treatments for serious medical conditions with high, unmet medical needs and relatively low marketing and development costs.

Its share price spike began with publication of its six-monthly interim results on 27 September, which showed further progress on its lead programme Lupuzor, which promises a potential breakthrough compound for life-threatening autoimmune disease Lupus. It has trials across the US, Europe and Mauritius and has just initiated first regulatory submissions to the US Food and Drug Administration and the European Medicines Agency.

Capital move

Last week, it also announced it had completed its sharing agreement, which saw Lanstead Capital buying around £5m of ordinary shares in the firm. Immupharma chairman Tim McCarthy said the agreement should create long-term shareholder value and help it hit “key milestones within our lead programme Lupuzor, as we get nearer to reporting top-line Phase III results in Q1 2018”. The shares jumped even higher on the news.

But investing in companies like Immupharma will always be risky. One setback for Lupuzor and its share price could crash. It also has to shoulder R&D costs, which totalled £2.3m in first half 2017. It therefore made a £3m loss for the period, on top of £3.7m in H1 2016. Total assets now stand at £6.4m, up from £5.5m on 31 December.

However City analysts are optimistic, expecting six years of negative earnings per share (EPS) to reverse in 2018, hitting 9p, with the company finally swinging into profit to make an anticipated £12m. The best might still be to come, although more of that potential upside is now factored into today’s higher share price.

Rolling out the barrels

Eland Oil & Gas (LSE: ELA) is also spiking today, its share price up more than 5% at time of writing. The Nigeria-based producer also published positive half-yearly results at the end of last month, with total gross production more than doubling, from 429,627 barrels of crude oil to 954,728 million.

The £145m company has a current cash balance of $27.3m, strengthened by a successful £15.2m equity placing in June, and CEO George Maxwell hailed a “very positive” first half as production restarted and boosted cashflow, with the near-term drilling programme now fully funded. 

EPS success

City analysts are rather bullish, forecasting EPS growth of a whopping 17,262% in full-year 2017, followed by another 199% in 2018. No wonder the share price is up 45% in a year, from 43p to today’s 64p. Lowly 2016 revenues of £2.37m are now forecast to hit £52.77m this year and £160.73m in 2018. If you reckon the oil price recovery has legs, Eland Oil & Gas could be a good way to play it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »